Biotechnology, Medical Health Aged Care 12/07/2023 12:41

Aegros Appoints Father of India’s Blood Plasma Industry as Chief Executive Officer of Aegros Asia

Aegros < 1 mins read

< 1 mins read

Good afternoon,

Please find attached a press release regarding the appointment of the father of India’s blood plasma industry, Dr. Ranjeet S. Ajmani, to the role of Chief Executive Officer of Aegros Asia.

Aegros is an Australian technology leader in the US$20B global therapeutic plasma market. Its GMP licensed HaemaFrac® lifts process yields to over 85%, reducing cost and carbon emissions while enhancing product safety.

For further comment or information, please contact:

Tim Cook: 0428 862 436

Karl Wolfenden: 0400 327 864

Contact details:

[email protected]

Media

More from this category

Biotechnology
12/12/2025
11:40

4DMedical Limited (ASX:4DX)

4DMedical secures $30.2 million with options underwrite

Highlights• $30.2 million in funding secured by entering into an underwriting agreement that ensures the exercise of all the 4DXO listed options• Additional funding results in a proforma cash balance as at 30 September 2025 of $63.7 million • 4DMedical is experiencing unprecedented interest in CT:VQ™, with multiple contract discussions underway, positioning CY26 as a transformational year Melbourne, Australia, 12 December 2025: 4DMedical Limited (ASX: 4DX, “4DMedical” or the “Company”) today announces it has entered into an option underwriting agreement (Underwriting Agreement) with Bell Potter Securities Limited (Underwriter) to fully underwrite the exercise of the 4DXO listed options on issue,…

Biotechnology
12/12/2025
10:58

EBR Systems, Inc. (ASX:EBR)

First implant in the Totally Leadless CRT (TLC-AU) Study

Key Highlights • First patient enrolment and implant in the Totally Leadless CRT (TLC-AU) study by Dr Paul Gould from the Princess Alexandra Hospital, Brisbane • TLC-AU is a feasibility study into using the WiSE® System alongside a leadless pacemaker to achieve totally leadless CRT • The study represents a significant strategic milestone as EBR evaluates WiSE as a potential first-line therapy for treating newly diagnosed heart failure patients • TLC-AU could meaningfully expand EBR’s addressable market Sunnyvale, California; 12 December 2025: EBR Systems, Inc., developer of the world’s only wireless cardiac pacing device for heart failure, announces the first…

Medical Health Aged Care
12/12/2025
10:11

Cosette Pharmaceuticals, Inc.

Termination of Proposed Acquisition of Mayne Pharma

BRIDGEWATER, N.J.–BUSINESS WIRE– Cosette Pharmaceuticals, Inc. (Cosette), a U.S.-based, fully integrated pharmaceutical company, confirms that on 9 December 2025 it served a notice on…

Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.

Book a demo Explore our plans